FDA Advisers Endorse the First Blood Test That Screens for Many Cancers

An FDA advisory panel has endorsed Grail’s Galleri, the blood test that looks for signs of dozens of cancers at once, voting that its benefits outweigh its risks for adults aged 50 and older. If the agency agrees, Galleri would become the first FDA-approved multi-cancer early detection (MCED) test — a genuinely new category in cancer screening. But the details of the vote, and of the evidence behind it, show a technology that is promising and still unproven where it matters most.

What the panel decided

On September 23, 2026, the FDA’s Molecular and Clinical Genetics Panel answered three separate questions. It was unanimous (10–0) that the test is safe. It was split 6–4 on whether it is effective. And it voted 7–2, with one abstention, that the benefits outweigh the risks. Grail filed its premarket approval application on January 29, 2026; the test has held FDA Breakthrough Device designation since 2018.

Background: why a multi-cancer test matters

Routine screening in the US exists for only a handful of cancers — breast, cervical, colorectal and, for some heavy smokers, lung. Cancers without a screening test account for roughly 70% of cancer deaths, and many of them — pancreatic, ovarian, liver, stomach — are usually found late, when treatment options narrow. The case for Galleri is simple: one blood draw that could flag some of those cancers before symptoms appear.

How Galleri works

Tumors shed fragments of DNA into the bloodstream. Galleri reads methylation patterns on that cell-free DNA — chemical tags that differ between cancerous and healthy tissue, and between tissue types. A machine-learning classifier then decides whether a cancer signal is present and, if so, predicts the cancer signal origin — the organ it most likely came from — so doctors know where to look first. A positive result is not a diagnosis; it triggers imaging and, often, a biopsy.

The evidence the panel weighed

Two large studies carried the application. In the North American PATHFINDER 2 study, adding Galleri to guideline screening found several times more cancers than standard screening alone, and roughly half of the Galleri-detected cancers were stage I or II. Specificity was about 99.6%, meaning well under 1% of people without cancer got a false alarm, and the predicted organ of origin was right about 94% of the time. About six in ten positive results turned out to be cancer.

The weak spot is sensitivity. Within a year of testing, Galleri caught only about four in ten of all cancers that were eventually diagnosed, rising to roughly seven in ten for a prespecified group of 12 especially deadly cancers. Many early, small tumors simply don’t shed enough DNA to detect — so a negative result is reassuring, but it is not an all-clear.

The UK trial that complicated the picture

The bigger question is whether finding cancers earlier actually saves lives. The randomized NHS-Galleri trial in England was designed to test a step toward that: whether screening reduced the number of cancers diagnosed at advanced stage III or IV. It missed that primary goal (hazard ratio 1.03). Secondary results were more encouraging — fewer stage IV diagnoses and about 16% more stage I and II cancers detected — but a missed primary endpoint in the largest randomized study is exactly why four panelists voted no on effectiveness. As one put it, the committee didn’t yet have the data to show the test is clinically effective.

The risks panelists worried about

Beyond effectiveness, panelists raised practical concerns: people treating a negative result as an all-clear and skipping mammograms or colonoscopies; doctors misreading results; the anxiety and cost of chasing false positives; and whether the health system has enough radiologists and endoscopists to handle the follow-up if millions of people are tested. Grail positions Galleri as a complement to, not a replacement for, standard screening, and it requires a prescription.

What happens next

Advisory votes are not binding, though the FDA usually follows them. Grail says it expects a decision in the coming months. Approval would matter commercially as much as clinically: Galleri is currently sold mostly as a cash-pay test at a list price of roughly $950, and an FDA label is the prerequisite for any realistic path to Medicare and broad private-insurance coverage. The FDA could also attach conditions, such as post-approval studies or label language stressing that the test does not replace existing screening.

What this means for patients

For now, nothing changes in recommended screening. If Galleri is approved, it would be one more option for adults 50 and older — most useful, on current evidence, for catching some cancers that have no other screening test, and least useful as a reason to skip the tests that already work. Anyone considering it should talk through with a doctor what a positive or negative result would and would not mean. This is regulatory news, not medical advice.